SHI Fanghong, LI Hao, LIU Xiaoyan, ZHANG Zaili. Evaluation of hypoglycemic drug-drug interactions by software[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 166-169. doi: 10.3969/j.issn.1006-0111.2018.02.014
| Citation:
|
SHI Fanghong, LI Hao, LIU Xiaoyan, ZHANG Zaili. Evaluation of hypoglycemic drug-drug interactions by software[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 166-169. doi: 10.3969/j.issn.1006-0111.2018.02.014
|
Evaluation of hypoglycemic drug-drug interactions by software
- 1.
Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
- 2.
Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
- Received Date: 2017-11-17
- Rev Recd Date:
2018-01-03
-
Abstract
Objective To evaluate and analyze the drug-drug interactions (DDI) of different antidiabetic drugs. Methods DDI database Lexi-InteractionTM was used to evaluate DDI for 28 commonly used antidiabetic medications (including insulin and 27 non-insulin preparations). Results 882 DDIs were identified for 28 drugs. Category C was the top rated DDI (69.8%). Category C, D, X were accounted for 91.2% of the total DDI. 28 medication combinations belonged to category X, which should be avoided to use together. Sulfonylureas had the most DDI, followed by metformin. Alpha-glucosidase inhibitors had least DDI. Conclusion Hypoglycemic drugs with less DDI, such as α-glycosidase inhibitors, glucagon-likepeptide1(GLP-1)analogs and sodium-dependent glucose transporters 2 inhibitor (SGLT2i)should be considered with high priority for patients taking multiple antidiabetic medications, elderly patients and patients with liver-kidney dysfunction.
-
References
|
[1]
|
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. Jama, 2013, 310(9):948-959. |
|
[2]
|
Doucet J,Chassagne P,Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults:a prospective study of 1000 patients[J]. J Am Geriatr Soc, 1996, 44(8):944-948. |
|
[3]
|
Hu DY, Pan CY, Yu JM,et al. The relationship between coronary artery disease and abnormal glucose regulation in China:the China Heart Survey[J]. Eur Heart J, 2006, 27(21):2573-2579. |
|
[4]
|
Zhu M, Li J, Li Z, et al. Mortality rates and the causes of death related to diabetes mellitus in Shanghai Songjiang District:an 11-year retrospective analysis of death certificates[J]. BMC Endocr Disord, 2015, 15:45. |
|
[5]
|
应令雯, 周健. 2017年ADA糖尿病医学诊疗标准解读[J]. 中国医学前沿杂志(电子版), 2017, 9(1):48-55. |
|
[6]
|
Lien D, Mader TJ. Survival from profound alcohol-related lactic acidosis[J]. J Emerg Med,1999,17(5):841-846. |
|
[7]
|
中国医师协会内分泌代谢科医师分会,中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1):1-10. |
|
[8]
|
母义明, 杨文英, 朱大龙,等. 磺脲类药物临床应用专家共识(2016年版)[J]. 药品评价, 2017, 14(1):5-12. |
|
[9]
|
van Giersbergen PL, Treiber A, Clozel M, et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide[J]. Clin Pharmacol Ther,2002,71(4):253-262. |
-
-
Proportional views
-
DownLoad: